Revisión
El papel del clevidipino en el tratamiento antihipertensivo: resultados clínicos
The role of clevidipine in hypertension management: Clinical results
Leído
3996
Vecesse ha leído el artículo
2497
Total PDF
1499
Total HTML
| año/Mes | Html | Total | |
|---|---|---|---|
| 2025 12 | 0 | 32 | 32 |
| 2025 11 | 1 | 97 | 98 |
| 2025 10 | 0 | 65 | 65 |
| 2025 9 | 0 | 24 | 24 |
| 2025 8 | 0 | 25 | 25 |
| 2025 7 | 0 | 22 | 22 |
| 2025 6 | 0 | 5 | 5 |
| 2025 5 | 0 | 3 | 3 |
| 2025 4 | 0 | 9 | 9 |
| 2025 3 | 1 | 15 | 16 |
| 2025 2 | 0 | 6 | 6 |
| 2025 1 | 0 | 7 | 7 |
| 2024 12 | 0 | 1 | 1 |
| 2024 11 | 0 | 3 | 3 |
| 2024 10 | 0 | 36 | 36 |
| 2024 9 | 0 | 41 | 41 |
| 2024 8 | 0 | 35 | 35 |
| 2024 7 | 0 | 29 | 29 |
| 2024 6 | 0 | 49 | 49 |
| 2024 5 | 0 | 39 | 39 |
| 2024 4 | 0 | 28 | 28 |
| 2024 3 | 0 | 44 | 44 |
| 2024 2 | 0 | 73 | 73 |
| 2024 1 | 0 | 43 | 43 |
| 2023 12 | 0 | 52 | 52 |
| 2023 11 | 1 | 81 | 82 |
| 2023 10 | 3 | 96 | 99 |
| 2023 9 | 0 | 42 | 42 |
| 2023 8 | 1 | 24 | 25 |
| 2023 7 | 0 | 30 | 30 |
| 2023 6 | 1 | 12 | 13 |
| 2023 5 | 1 | 5 | 6 |
| 2023 4 | 1 | 0 | 1 |
| 2023 3 | 8 | 0 | 8 |
| 2023 2 | 0 | 12 | 12 |
| 2022 1 | 0 | 5 | 5 |
| 2022 12 | 0 | 4 | 4 |
| 2022 11 | 0 | 7 | 7 |
| 2022 10 | 0 | 1 | 1 |
| 2022 9 | 0 | 25 | 25 |
| 2022 8 | 0 | 4 | 4 |
| 2022 7 | 0 | 2 | 2 |
| 2022 6 | 0 | 3 | 3 |
| 2022 5 | 2 | 7 | 9 |
| 2022 4 | 0 | 5 | 5 |
| 2022 3 | 0 | 1 | 1 |
| 2021 1 | 2 | 2 | 4 |
| 2021 12 | 0 | 4 | 4 |
| 2021 11 | 0 | 4 | 4 |
| 2021 10 | 3 | 3 | 6 |
| 2021 9 | 0 | 1 | 1 |
| 2021 8 | 0 | 2 | 2 |
| 2021 7 | 0 | 1 | 1 |
| 2021 6 | 0 | 3 | 3 |
| 2021 5 | 5 | 5 | 10 |
| 2021 4 | 0 | 4 | 4 |
| 2021 2 | 0 | 3 | 3 |
| 2020 1 | 1 | 7 | 8 |
| 2020 11 | 1 | 3 | 4 |
| 2020 10 | 0 | 2 | 2 |
| 2020 9 | 2 | 5 | 7 |
| 2020 8 | 0 | 30 | 30 |
| 2020 6 | 5 | 13 | 18 |
| 2020 5 | 0 | 6 | 6 |
| 2020 4 | 0 | 25 | 25 |
| 2020 3 | 0 | 23 | 23 |
| 2020 2 | 0 | 16 | 16 |
| 2020 1 | 3 | 41 | 44 |
| 2019 12 | 0 | 55 | 55 |
| 2019 11 | 0 | 62 | 62 |
| 2019 10 | 0 | 56 | 56 |
| 2019 9 | 0 | 34 | 34 |
| 2019 8 | 0 | 28 | 28 |
| 2019 7 | 0 | 58 | 58 |
| 2019 6 | 1 | 36 | 37 |
| 2019 5 | 0 | 75 | 75 |
| 2019 4 | 2 | 45 | 47 |
| 2019 3 | 1 | 22 | 23 |
| 2019 2 | 2 | 25 | 27 |
| 2019 1 | 0 | 14 | 14 |
| 2018 12 | 0 | 11 | 11 |
| 2018 11 | 2 | 18 | 20 |
| 2018 10 | 1 | 16 | 17 |
| 2018 6 | 0 | 1 | 1 |
| 2018 3 | 1 | 0 | 1 |
| 2018 2 | 6 | 1 | 7 |
| 2018 1 | 1 | 0 | 1 |
| 2017 9 | 0 | 1 | 1 |
| 2017 8 | 0 | 7 | 7 |
| 2017 7 | 32 | 9 | 41 |
| 2017 6 | 50 | 21 | 71 |
| 2017 5 | 94 | 33 | 127 |
| 2017 4 | 62 | 20 | 82 |
| 2017 3 | 82 | 36 | 118 |
| 2017 2 | 70 | 24 | 94 |
| 2016 1 | 51 | 7 | 58 |
| 2016 12 | 57 | 15 | 72 |
| 2016 11 | 111 | 30 | 141 |
| 2016 10 | 101 | 26 | 127 |
| 2016 9 | 67 | 32 | 99 |
| 2016 8 | 55 | 24 | 79 |
| 2016 7 | 66 | 8 | 74 |
| 2016 6 | 64 | 35 | 99 |
| 2016 5 | 70 | 43 | 113 |
| 2016 4 | 74 | 32 | 106 |
| 2016 3 | 59 | 20 | 79 |
| 2016 2 | 51 | 31 | 82 |
| 2015 1 | 36 | 27 | 63 |
| 2015 12 | 47 | 27 | 74 |
| 2015 11 | 3 | 9 | 12 |
| 2015 10 | 1 | 8 | 9 |
| 2015 9 | 1 | 5 | 6 |
| 2015 8 | 2 | 2 | 4 |
| 2015 7 | 0 | 2 | 2 |
| 2015 6 | 1 | 3 | 4 |
| 2015 5 | 1 | 3 | 4 |
| 2015 4 | 5 | 7 | 12 |
| 2015 3 | 32 | 3 | 35 |
| 2015 2 | 18 | 2 | 20 |
| 2015 1 | 26 | 8 | 34 |
| 2014 12 | 38 | 19 | 57 |
| 2014 11 | 13 | 9 | 22 |
Mostrar todo
